Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. The Global Burden of Cancer
     3.1 Cancer - A Leading Cause of Death
     3.2 Current and Future Cancer Cases: By Type and Geography
     3.3 Common Causes of Cancer

4. Global Cancer Market Outlook to 2017
     4.1 Current and Future Growth
     4.2 Analysis by Therapeutic Sub-Segments

5. Monoclonal Antibodies: Introduction and Working
     5.1 Types of mAbs
            5.1.1 Murine Antibodies
            5.1.2 Chimeric and Humanized Antibodies
            5.1.3 Fully Human Antibodies
     5.2 Conjugated Cancer Therapies using mAbs
            5.2.1 Radioimmunotherapy
            5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
            5.2.3 Immunoliposomes
            5.2.4 Immunotoxin
            5.2.5 Immunocytokine
     5.3 Cancer Monoclonal Antibody Therapies
            5.3.1 Avastin (Bevacizumab)
            5.3.2 Rituxan (Rituximab)
            5.3.3 Herceptin (Trastuzumab)
            5.3.4 Erbitux (Cetuximab)
            5.3.5 Vectibix (Panitumumab)
            5.3.6 Zevalin (Ibritumomab)
            5.3.7 Bexxar (Tositumomab)
            5.3.8 Xgeva (Denosumab)
            5.3.9 Arzerra (Ofatumumab)
            5.3.10 Yervoy (Ipilimumab)
            5.3.11 Adcetris (Brentuximab Vedotin)
            5.3.12 Perjeta (Pertuzumab)
            5.3.13 Kadcyla (Ado-trastuzumab Emtansine)

6. Industry Trends and Drivers
     6.1 Strategic Activities or Alliances on Rise
     6.2 New Clinical Approvals Showing Promising Future
     6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
     6.4 Antibody Drug Conjugates for Cancer Therapy

7. Global Cancer mAbs Market Outlook to 2017
     7.1 Market Size
     7.2 Cancer mAbs: Approval History and Market Share
     7.3 Cancer mAbs: Current and Future Market Size
            7.3.1 Avastin (Bevacizumab)
            7.3.2 MabThera/Rituxan (Rituximab)
            7.3.3 Herceptin (Trastuzumab)
            7.3.4 Erbitux (Cetuximab)
            7.3.5 Vectibix (Panitumumab)
     7.4 Country-Level Analysis
            7.4.1 US
            7.4.2 Japan
            7.4.3 Europe
     7.5 Market Share of Key Players

8. Pipeline Analysis of Cancer Monoclonal Antibodies

9. Competitive Landscape
     9.1 Roche
     9.2 Eli Lilly
     9.3 GlaxoSmithKline
     9.4 Amgen
     9.5 Bristol-Myers Squibb
     9.6 Seattle Genetics
     9.7 Spectrum Pharmaceuticals
     9.8 Genmab